# Apyx Medical Corp: Form 10-Q for the period ended Sep 30, 2009

- Company: [Apyx Medical Corp](/companies/apyx.md) (CIK 719135)
- Form: 10-Q
- Filed: 2009-11-09
- Accepted by EDGAR: Nov 9, 2009, 08:03 ET
- Period: 2009-09-30
- Accession: 0001140361-09-025165
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/719135/000114036109025165/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/719135/000114036109025165/

## Management's discussion and analysis

As filed, 32,856 characters.

### Cautionary Notes Regarding “Forward-Looking” Statements

This report contains statements that we believe to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give our current expectations or forecasts of future events. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project,” or “continue,” or similar words or the negative thereof. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Any or all of our forward-looking statements in this report and in any public statements we make could be materially different from actual results. They can be affected by assumptions we might make or by known or unknown risks or uncertainties. Consequently, we cannot guarantee any forward-looking statements. Investors are cautioned not to place undue reliance on any forward-looking statements. Investors should also understand that it is not possible to predict or identify all such factors and should not consider the following list to be a complete statement of all potential risks and uncertainties. The following factors and those discussed in ITEM 1A, Risk Factors, included in our Annual Report on Form 10-K for the year ended December 31, 2008, may affect the achievement of forward-looking statements:

- general economic and political conditions, such as political instability, credit market uncertainty, the rate of economic growth or decline in our principal geographic or product markets or fluctuations in exchange rates; continued deterioration in or stabilization of the global economy;
- changes in general economic and industry conditions in markets in which we participate, such as:
- continued deterioration in or destabilization of the global economy;
- continued deterioration in or destabilization of the North America housing market;
- the strength of product demand and the markets we serve;
- the intensity of competition, including that from foreign competitors;
- pricing pressures;
- the financial condition of our customers;
- market acceptance of new product introductions and enhancements;
- the introduction of new products and enhancements by competitors;
- our ability to maintain and expand relationships with large customers;
- our ability to source raw material commodities from our suppliers without interruption and at reasonable prices; and
- our ability to source components from third parties, in particular from foreign manufacturers, without interruption and at reasonable prices;
- our ability to access capital markets and obtain anticipated financing under favorable terms;
- our ability to identify, complete and integrate acquisitions successfully and to realize expected synergies on our anticipated timetable;
- changes in our business strategies, including acquisition, divestiture and restructuring activities;
- changes in operating factors, such as continued improvement in manufacturing activities, the achievement of related efficiencies and inventory risks due to shifts in market demand;
- our ability to generate savings from our cost reduction actions;
- unanticipated developments that could occur with respect to contingencies such as litigation, intellectual property matters, product liability exposures and environmental matters; and
- our ability to accurately evaluate the effects of contingent liabilities.

The foregoing factors are not exhaustive, and new factors may emerge or changes to the foregoing factors may occur that would impact our business. We assume no obligation, and disclaim any duty, to update the forward-looking statements in this report.

### Overview

We are a medical device company engaged in the manufacturing and marketing of electrosurgical devices. Our medical products include electrosurgical generators and accessories, saline enhanced resection devices, endoscopic disposable and reusable modular instruments, cauteries, medical lighting, nerve locators and other products.

We internally divide our operations into three product lines: electrosurgical products, battery operated cauteries and other products. The electrosurgical product line sells electrosurgical products that include dessicators, generators, electrodes, electrosurgical pencils and various ancillary disposable products. These products are used in surgery for the cutting and coagulation of tissue. Battery operated cauteries are used for precise hemostasis (to stop bleeding) in ophthalmology and in other fields. Our other revenues are derived from nerve locators, disposable and reusable penlights, medical lighting, license fees, development fees and other miscellaneous income.

We market most of our products through medical distributors, which distribute to more than 6,000 hospitals, as well as doctors and other health-care facilities. Our products are sold in more than 150 countries through local distributors coordinated by our in-house sales and marketing personnel at our Clearwater, Florida facility. We have no manufacturing facilities or branch offices other than the Florida and Canadian facilities.

Our ten largest customers accounted for approximately 73% and 69% of net revenues for the first nine months of 2009 and 2008 respectively. At September 30, 2009 and 2008, our ten largest trade receivables accounted for approximately 62% and 67% of our net receivables, respectively. In the first nine months of 2009 and 2008, one customer accounted for 25% and 19% of total sales, respectively.

Our business is generally not seasonal in nature.

### Recent Developments and Outlook for Remainder of 2009 and Early 2010

We continue to seek growth by developing new technologies. We are encouraged by the positive surgeon acceptance of our Saline Enhanced Electrosurgical Resection (SEER) tissue resection device. In the third quarter, we filed with the Food and Drug Administration (FDA) a 510K application for the BOSS orthopedic device. The BOSS is an expansion of our sintered steel technology and companion to the SEER. SEER and BOSS are high margin products that address markets exceeding $500 million. We are establishing a marketing program which includes specialty sales teams to deliver the BOSS and SEER products into the marketplace.

During the early part of the third quarter, we filed with the FDA a 510K application for our Seal-n-Cut™ vessel sealing instrument line as well as a separate application for our ICON VS generator, which is designed to work with the Seal-n-Cut™ instruments. The vessel sealing market is estimated to exceed $1.0 billion, annually.

In August 2009, we received clearance to market our J-Plasma technology (ICON GS). J-Plasma includes an improved redesigned system with added features to increase efficiency for the surgeon, while reducing manufacturing costs. We are developing marketing strategies for J-Plasma, and believe the product will be versatile, with uses in a range of surgical specialties.

We remain focused on maximizing shareholder value through developing new products that provide high margins and growth opportunities.

### Results of Operations

#### Sales

*(in thousands)*

| Sales by Product Line | Three months ended September 30, 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Electrosurgical | $4,217 | $5,139 | (17.9%) | $14,126 | $14,480 | (2.4%) |
| Cauteries | 1,575 | 1,532 | 2.8% | 4,623 | 4,673 | (1.1%) |
| Other | 579 | 625 | (7.4%) | 1,671 | 1,806 | (7.5%) |
| Total | $6,371 | $7,296 | (12.7%) | $20,420 | $20,959 | (2.6%) |

| Sales by Domestic and International (in thousands) | Three months ended September 30, 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Domestic | $5,506 | $6,348 | (13.3%) | $17,121 | $17,294 | (1.0%) |
| International | 865 | 948 | (8.8%) | 3,299 | 3,665 | (10.0%) |
| Total | $6,371 | $7,296 | (12.7%) | $20,420 | $20,959 | (2.6%) |

Sales for the third quarter 2009 decreased approximately $924,000 or 12.7% compared to the same period in 2008. This decrease was due to the following reasons:

- sales of generators were down $629,000 or 19.5% due to lower capital expenditures by hospitals and doctor offices in the current economy;
- sales of electrosurgical disposables were down $292,000 or 15.3% because distributors elected to reduce their inventories in the current economy; and
- international sales decreased by $83,000 or 8.7% due to periods of a stronger dollar coupled with the global economic slowdown.

Sales for the nine months ended September 30, 2009 decreased $538,000 or 2.6% compared to the same period in 2008. This decrease was due to the following reasons:

- international sales decreased by $366,000 or 10.0% due to periods of a stronger dollar coupled with the global economic slowdown;
- sales of generators were down $1,190,000 or 12.1% due to lower capital expenditures by hospitals and doctor offices in the current economy;
- cautery sales were down $50,000 or 1.0%; and
- other products were down $135,000 or 12.1%, mainly due to installment revenue that ended in September 2008.

These decreases were offset by the sale of electrosurgical disposables, which increased $835,000 or 15.3%, mainly due to the sale of ablators.

#### Gross Profit

*(in thousands)*

|  | Three months ended September 30, 2009 | 2008 | Percent of sales 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 | 2009 | Percent of sales 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cost of sales | $3,611 | $4,062 | 56.7% | 55.7% | (11.1%) | $11,359 | $12,239 | 55.6% | 58.4% | (7.2%) |
| Gross profit | $2,760 | $3,233 | 43.3% | 44.3% | (14.6%) | $9,061 | $8,720 | 44.4% | 41.6% | 3.9% |

The 1.0% decrease in gross profit as a percentage of sales in the third quarter of 2009 from 2008 was primarily a result of increases in international freight cost for parts manufactured overseas and in labor costs as a percentage of sales.

This decrease in gross profit as a percentage of sales in the third quarter of 2009 from 2008 was partially offset by:

- a $35,000 reduction in annual bonuses; and
- a $40,000 reduction of our company match to our employees’ 401(k) contributions.

Gross profit for the nine month period ended September 30, 2009 increased 2.8% as a percentage of sales as compared to the same period in 2008. This was the result of:

- a $447,000 increase in capitalized manufacturing overhead;
- a $105,000 reduction in annual bonuses;
- a $120,000 reduction of our company match to our employees’ 401(k) contributions; and
- an $835,000 increase in sales of electrosurgical disposables, mainly due to the sale of ablators, which are higher margin products.

These increases were partially offset by a $150,000 increase in international freight cost for parts manufactured overseas.

#### Gain on Cancellation of Agreement

*(in thousands)*

|  | Three months ended September 30, 2009 | 2008 | Percent of sales 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 | 2009 | Percent of sales 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Gain on Cancellation of Agreement | $– | $– | – | – | – | $– | $1,496 | – | 7.1% | – |

During the nine months ended September 30, 2008, we recognized a gain from a cancellation of a contract with Boston Scientific Corporation of approximately $1.5 million. We had no such activity in 2009. For an explanation of this gain, please see Note 1, Basis of Presentation, to our unaudited consolidated financial statements included in this report.

#### Research and Development Expense

*(in thousands)*

|  | Three months ended September 30, 2009 | 2008 | Percent of sales 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 | 2009 | Percent of sales 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| R & D Expense | $496 | $488 | 7.8% | 6.7% | 1.6% | $1,497 | $1,430 | 7.3% | 6.8% | 4.7% |

Research and development expense increased $7,755 or 1.6% in the third quarter of 2009 from 2008. This increase was primarily a result of:

- a $34,000 increase in staffing costs to support the J-Plasma product line; and
- a $16,000 increase in validation costs related to our new Icon generators (GS, GP, VS).

These increases were partially offset because we capitalized various costs incurred to make test fixtures to support the Seal-n-Cut™ product development at Bovie Canada in the current quarter. Previously, these costs were expensed.

The $67,000 or 4.7% increase in research and development expense for the nine months ended September 30, 2009 from the same period in 2008 was primarily a result of:

- a $119,000 increase in staffing costs to support the J-Plasma and sintered steel product lines; and
- a $10,000 increase in validation costs related to our new Icon generators (GS, GP, VS).

These increases were partially offset because we capitalized various costs incurred to make test fixtures to support the Seal-n-Cut™ product development at Bovie Canada during the nine month period ended September 30, 2009. Previously, these costs were expensed.

#### Professional Fees

*( in thousands)*

|  | Three months ended September 30, 2009 | 2008 | Percent of sales 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 | 2009 | Percent of sales 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Professional services | $303 | $345 | 4.8% | 4.7% | (12.0%) | $1,024 | $667 | 5.0% | 3.2% | 53.5% |

Professional fees decreased $41,000 or 12.0% in the third quarter of 2009 compared to the same period in 2008. This decrease was primarily because:

- we incurred $36,000 in consulting costs related to the Erbe lawsuit in 2008 that did not recur in 2009; and
- our legal fees for the Erbe lawsuit decreased by $28,000 in the third quarter of 2009 because the parties began working towards a settlement of the dispute.

This decrease was offset by a $23,000 increase in accounting fees for tax-related work for (a) quarterly tax returns and (b) compliance with FASB ASC Topic 740-10-05, *Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109* (FASB Interpretation No. 48).

Professional fees increased $357,000 or 53.5% for the nine months ended September 30, 2009 from the same period in 2008. This increase was primarily because:

- accounting fees increased by $65,000 due to tax related work and the timing of auditing fees related to our employee 401(k) plan, which were incurred earlier in 2009; and
- legal fees increased by $267,000 due to work related to the Erbe lawsuit and to responding to the SEC’s periodic review of our Annual Report on Form 10-K for the year ended December 31, 2008.

#### Salaries

*( in thousands)*

|  | Three months ended September 30, 2009 | 2008 | Percent of sales 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 | 2009 | Percent of sales 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Salaries & related cost | $759 | $727 | 11.9% | 10.0% | 4.5% | $2,304 | $2,253 | 11.3% | 10.8% | 2.3% |

Salaries increased by $32,000 or 4.5% in the third quarter of 2009 compared to the same period 2008. This increase was primarily a result of:

- a $25,000 increase in staffing costs to support the domestic direct sales of the SEER product line;
- a $6,000 increase in overall employee benefits and health insurance related costs; and
- an $8,000 increase in the accrual for vacation pay related to higher-level employees.

These increases were offset by:

- a $12,000 reduction in annual bonuses;
- a $14,000 reduction of our company match to our employees’ 401(k) contributions; and
- a $6,000 reduction of a position in Bovie Canada.

Salaries increased by $51,000 or 2.3 % for the nine months ended September 30, 2009 from the same period in 2008. This increase was primarily a result of:

- a $56,000 increase in staffing costs to support the domestic direct sales of the SEER product line;
- a $25,000 increase in overall employee benefits and health insurance related costs; and
- a $14,000 increase in the accrual for vacation pay related to higher-level employees.

These increases were offset by:

- a $37,000 reduction in annual bonuses;
- a $40,000 reduction of our company match to our employees’ 401(k) contributions; and
- a $6,000 reduction of a position in Bovie Canada.

#### Selling, General & Administrative Expenses

*(in thousands)*

|  | Three months ended September 30, 2009 | 2008 | Percent of sales 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 | 2009 | Percent of sales 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| SG & A costs | $1,312 | $1,061 | 20.6% | 14.5% | 23.6% | $3,532 | $3,221 | 17.3% | 15.4% | 9.6% |

Selling, general and administrative costs increased $251,000 or 23.6% in the third quarter of 2009 compared to the same period of 2008. This increase was primarily a result of:

- a $160,000 accrual for the settlement of the Erbe lawsuit;
- a $58,000 increase in property taxes related to our new facility in Clearwater, Florida;
- a $33,000 increase in electricity costs related to the new larger facility;
- a $25,000 increase in amortization expense related to new products;
- a $22,000 increase in insurance expense due to the new larger facility as well as insurance on our old building listed for sale;
- a $14,000 increase in telephone expense due to an expansion of our communication infrastructure and related costs; and
- a $5,000 increase in depreciation expense attributable to Bovie Canada during the 2009 period versus 2008.

These increases were partially offset by:

- a $50,000 decrease in travel costs;
- a $36,000 decrease in advertising costs; and
- a $40,000 decrease in administrative costs in Bovie Canada.

Selling, general and administrative costs increased $310,000 or 9.6 % for the nine months ended September 30, 2009 from the same period in 2008. This increase was primarily a result of:

- a $160,000 accrual for the settlement of the Erbe lawsuit;
- a $94,000 increase in taxes related to our new facility in Clearwater Florida;
- an $86,000 increase in electricity costs related to the new larger facility;
- an $84,000 increase in amortization expense related to new products;
- a $47,000 increase in telephone expense due to an expansion of our communication infrastructure and related costs;
- a $33,000 increase in insurance expense due to the new larger facility as well as insurance on our old building listed for sale; and
- a $30,000 increase in depreciation expense attributable to Bovie Canada during the 2009 period versus 2008.

These increases were partially offset by:

- a $118,000 decrease in travel costs;
- an $85,000 decrease in advertising costs; and
- a $52,000 decrease in administrative costs in Bovie Canada.

#### Other Income

*(in thousands)*

|  | Three months ended September 30, 2009 | 2008 | Percent of sales 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 | 2009 | Percent of sales 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest income (expense) | $(55) | $(15) | (0.9%) | (0.2%) | (261%) | $1 | $15 | 0.0% | 0.1% | (91%) |

Net interest expense increased by $40,000 or 261% in the three months ended September 30, 2009 as compared to the same period in 2008 due to interest expense related to the industrial revenue bonds used to finance our new facility.

For the nine-month period ended September 30, 2009 when compared to the same period in 2008, net interest income decreased by $14,000, primarily as a result of interest expense related to the industrial revenue bonds used to finance our new facility.

#### Income Taxes

*(in thousands)*

|  | Three months ended September 30, 2009 | 2008 | Percent of sales 2009 | 2008 | Percent change 2009 | Nine months ended September 30, 2008 | 2009 | Percent of sales 2008 |  | Percent change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Income before inc. taxes | $(166) | $597 | (2.6%) | 8.2% | (128%) | $705 | $2,659 | 3.5% | 12.7% | (73.5%) |
| Benefit (Provision) taxes | $128 | $(232) | 2.0% | (3.2%) | (155%) | $(137) | $(866) | (0.7%) | (4.1%) | (84.2%) |
| Effective tax rate | – | 38.9% |  |  |  | 19.4% | 32.6% |  |  |  |

For the nine months ended September 30, 2009 and 2008, we recorded provisions for income taxes of $137,000 and $866,000, respectively. The effective tax rates for the nine months ended September 30, 2009 and 2008 were 19.4% and 32.6%, respectively. The difference between the provision for income taxes and the income tax determined by applying the statutory federal income tax rate of 34% is due primarily to the existence of research and development tax credits and return to provision adjustments.

We estimate that our annual effective tax rate is approximately 34%. We adjust our income tax provision for both temporary and permanent differences between net taxable income according to the codification of accounting principles and net taxable income pursuant to the Internal Revenue Code and other state income tax codes.

### Product Development

We have developed most of our products and product improvements internally. Funds for this development have come primarily from our internal cash flow and from the proceeds of the exercise of stock options. We maintain close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and development. New and improved products play a critical role in our sales growth. We continue to emphasize the development of proprietary products and product improvements to complement and expand our existing product lines. We have a centralized research and development focus, with our Florida and Canadian manufacturing locations responsible for new product development and product improvements. Our research, development and engineering units at the manufacturing locations maintain relationships with distribution locations and customers to provide an understanding of changes in the market and product needs. During 2009, we continued to invest in ICON GS (J-Plasma technology), ICON GP, vessel sealing technology, Polarian and BOSS. We intend to pay the ongoing cost for this development from operating cash flows.

In the next year, we do not contemplate any material purchase or acquisition of assets that our ordinary cash flow and/or credit line would be unable to sustain.

### Reliance on Collaborative, Manufacturing and Selling Arrangements

We depend on certain contractual OEM customers for product development. In these situations, we plan to manufacture the products developed. The customer has no legal obligation, however, to purchase the developed products. If the collaborative customer fails to give us purchase orders for the product after development, our future business and value of related assets could be negatively affected. Furthermore, we can give no assurance that a collaborative customer may give sufficient high priority to our products. In addition, disagreements or disputes may arise between Bovie and our contractual customers, which could adversely affect production of our products. We also have informal collaborative arrangements with two foreign suppliers in which we request the development of certain items and components, and we purchase them pursuant to purchase orders. Our purchase orders are never longer than one year and are supported by orders from our customers.

### Liquidity and Capital Resources

Our working capital at September 30, 2009 was $10.1 million as compared to $9.7 million at December 31, 2008. Accounts receivable day sales outstanding were 33.2 days and 37.0 days at September 30, 2009 and September 30, 2008, respectively.

We generated cash from operations of approximately $421,000 for the nine months ended September 30, 2009 compared to approximately $707,000 for the same period of 2008, a decrease of approximately $286,000.

In the nine-month period ended September 30, 2009, we used $2.2 million for the purchase of property and equipment as compared to purchases of such assets of approximately $635,000 in 2008. The increase resulted primarily from our refurbishment of our new facility that we purchased in September 2008.

We generated cash from financing activities of approximately $2.2 million and $218,000 during the nine months ended September 30, 2009 and 2008, respectively. The increase in cash resulted primarily from borrowings under our line of credit of approximately $1.0 million and cash that was released from an escrow account established to fund the refurbishment of our new facility.

We had approximately $2.9 million in cash and cash equivalents at September 30, 2009. We believe our cash on hand, as well as anticipated cash flows from operations, will be sufficient to fund our operating capital requirements, capital expenditures and any acquisitions to supplement our current product offerings for a period of at least one year. If we need additional funds, we have $4.0 million of borrowing capacity available under our existing credit facility. As of September 30, 2009, the outstanding balance on our line of credit was $1.0 million.

### Off-Balance Sheet Arrangements

As of September 30, 2009, we had future contractual obligations for certain employee agreements, purchase order commitments and operating leases as follows:

*(in thousands)*

|  | As of September 30, 2009 | 2010 | 2011 | 2012 | 2013 |
| --- | ---: | ---: | ---: | ---: | ---: |
| Operating leases | $70 | $278 | $252 | $246 | $223 |
| Employment agreements | $260 | $865 | $871 | $881 | $947 |
| Purchase order commitments | $3,069 | $– | $– | $– | $– |

### Critical Accounting Estimates

We have adopted various accounting policies to prepare the consolidated financial statements in accordance with accounting principles generally accepted in the United States. Our most significant accounting policies are disclosed in Note 1 to the consolidated financial statements included in our Form 10-K for the year ended December 31, 2008.

The preparation of the consolidated financial statements, in conformity with the Codification of accounting principles, requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to bad debts, inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts and income taxes, are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances, and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates. In addition, stock-based compensation expense represents a significant estimate as it is based on a formula that in part encompasses the future but unknown value of our common stock. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the period that they are determined to be necessary. It is at least reasonably possible that our estimates could change in the near term with respect to these matters.

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain when the accounting estimates are made, and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

#### Allowance for Doubtful Accounts

We maintain an allowance for doubtful accounts for estimated losses in the collection of accounts receivable. We make estimates regarding the future ability of our customers to make required payments based on historical credit experience and expected future trends. If actual customer financial conditions are less favorable than projected by management, additional accounts receivable write-offs may be necessary, which would unfavorably affect our future operating results.

#### Inventory Reserves

We maintain reserves for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. These marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.

#### Long-Lived Assets

We review long-lived assets that are held and used, including property and equipment and intangible assets, for impairment whenever changes in circumstances indicate that the carrying amount of the assets may not be recoverable. These evaluations compare the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset over its expected useful life and are significantly affected by estimates of future prices and volumes for our products, capital needs, economic trends and other factors that are inherently difficult to forecast. If the asset is considered to be impaired, we record an impairment charge equal to the amount by which the carrying value of the asset exceeds its fair value determined by either a quoted market price, if any, or a value determined by using a discounted cash flow technique.

#### Share-based Compensation

Under our stock option plan, our board of directors may grant options to purchase our common shares to our key employees, officers, directors and consultants. We account for stock options in accordance with FASB ASC Topic 718-10-10, *Share-Based Payment* (SFAS 123R), with option expense amortized over the vesting period based on the binomial lattice option-pricing model fair value on the grant date, which includes a number of estimates that affect the amount of our expense.

#### Income Taxes

We operate in multiple tax jurisdictions both inside and outside the United States. Accordingly, we must determine the appropriate allocation of income to each of these jurisdictions. Tax audits associated with the allocation of this income and other complex issues may require an extended period of time to resolve and may result in income tax adjustments if changes to the income allocation are required between jurisdictions with different tax rates. Because tax adjustments in certain jurisdictions can be significant, we record accruals representing our best estimate of the probable resolution of these matters. To the extent additional information becomes available, we adjust these accruals to reflect the revised estimated probable outcome.

#### Other Matters

We distribute our products throughout the world. As a result, our financial results could be significantly affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets. Our operating results are primarily exposed to changes in exchange rates among the U.S. dollar and European currencies, in particular the euro and the British pound. When the U.S. dollar weakens against foreign currencies, the dollar value of sales denominated in foreign currencies increases. When the U.S. dollar strengthens, the opposite situation occurs. We manufacture our products in the United States, China, Canada and Bulgaria and incur the costs to manufacture in the U.S. dollar. This worldwide deployment of factories serves to partially mitigate the impact of the high costs of manufacturing in the U.S.

## Market risk

As filed, 2,957 characters.

### Interest Rate Risk

Our financial instruments include cash, cash equivalents and short-term investments. We are exposed to interest rate risk on our short-term investments. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest in highly liquid overnight money market investments. To minimize our exposure due to adverse shifts in interest rates, we invest in short-term overnight securities. If a 10% change in interest rates were to have occurred on September 30, 2009, this change would not have had a material effect on the fair value of our investment portfolio as of that date. Due to the short holding period of our investments, we have concluded that we do not have a material financial market risk exposure.

### Foreign Currency Risk

Although we have a foreign subsidiary located in Canada, our transactions outside our functional currency are minimal and not a material financial risk.

### Changes in Market and Counterparty Risk

The global recession, driven initially by the crisis in global credit and financial markets, has caused extreme disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that there will not be further deterioration in credit and financial markets and confidence in economic conditions. These economic uncertainties affect businesses such as ours in a number of ways, making it difficult to accurately forecast and plan our future business activities. The current constriction of credit in financial markets may continue to lead hospitals and physicians to postpone spending, which may cause our customers to aggressively manage their inventories and delay their future orders with us. In addition, some of our suppliers and other vendors may be adversely impacted by tightening of the credit markets, fluctuations in commodity prices and other consequences of the economic downturn. Some vendors may seek to change the terms on which they do business with us to lessen the impact of the economic downturn on their business. If we are forced to find alternative vendors for key components or services, whether due to demands from the vendor or the vendor’s bankruptcy or ceasing operations, that could be a distraction to us and adversely impact our business. Changing vendors could also result in our inability to obtain business terms as favorable to us as the terms on which we currently operate. We are unable to predict the likely duration and severity of the current disruptions in the credit and financial markets and adverse global economic conditions, and if the current uncertain economic conditions continue or further deteriorate, our business and results of operations could be materially and adversely affected.

## Controls and procedures

As filed, 1,715 characters.

### Evaluation of Disclosure Controls and Procedures

We have carried out an evaluation, under the supervision of and with the participation of our management, including our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of September 30, 2009. Based upon that evaluation, our CEO and CFO concluded that, as of September 30, 2009, our disclosure controls and procedures are effective in providing reasonable assurance that (a) the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (b) such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

### Changes in Internal Controls

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2009 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 200 characters.

There have been no material changes to the Risk Factors previously disclosed in our Form 10-K and 10-K/A for the year ended December 31, 2008, in response to Item 1A to Part 1 of Form 10-K and 10-K/A.

Filed Nov 9, 2009.
Source: SEC EDGAR, the filing index for accession 0001140361-09-025165. Last ingested by Listed: Nov 5, 2026, 13:09 ET. No prices; not investment advice.
